<DOC>
	<DOCNO>NCT03009760</DOCNO>
	<brief_summary>The purpose study compare pharmacokinetics pharmacodynamics CJ-12420 single multiple dose administration accord H. pylorus infection .</brief_summary>
	<brief_title>To Investigate Pharmacokinetics Pharmacodynamics CJ-12420 After Single Multiple Dose Administration</brief_title>
	<detailed_description>1 . Cohort 1 : To investigate pharmacokinetics pharmacodynamics CJ-12420 multiple dose administration H. pylori negative volunteer . 2 . Cohort 2 : To investigate pharmacokinetics pharmacodynamics CJ-12420 single dose administration H. pylori positive volunteer .</detailed_description>
	<criteria>Healthy male volunteer 20 45 year age ( inclusive ) Body mass index ( BMI ) range 19~28 kg/㎡ weight least 50kg Medically healthy clinically significant vital sign ( blood pressure sit position , pulse rate ) 90 mmHg ≤ systolic blood pressure ≤ 140 mmHg 50 mmHg ≤ diastolic blood pressure ≤ 95 mmHg 45 beat per minute ≤ pulse rate ≤ 95 beat per minute Understood requirement study voluntarily consent participate study Agreed sexually abstinent use condom spermicide engage sexual activity donate sperm course study 30 day follow completion study Nonsmokers nonusers nicotinecontaining product least 1 year [ Cohort 1 ] H. pylorus negative determine urea breath test serum IgG antibody [ Cohort 2 ] H. pylorus positive determine urea breath test serum IgG History clinically significant gastrointestinal , renal , hepatic , neurologic , hematooncologic , endocrine , pulmonary , immunologic , psychiatric , musculoskeletal , cardiovascular disease condition , opinion investigator , would jeopardize safety subject impact validity study result History allergy hypersensitivity drug , include prior serious adverse reaction PPIs PCABs Undergone surgery medical condition , judgment PI investigator may affect absorption , distribution , metabolism elimination study drug Administered drug ( ) clinical study within 60 day prior screen visit Donated blood within 60 day blood component within 30 day , transfuse plasma within 30 day prior screen visit On special diet experience substantial change eat habit within 30 day prior screen visit Used prescription medication within 14 day , OTC medication include herbal product within 7 day prior screen visit Consumed 21 units/week alcohol Consumed 5 units/day caffeinecontaining beverage Positive urine screen drug and/or cotinine Positive blood screen human immunodeficiency virus ( HIV ) , hepatitis B C , syphilis Clinically significant abnormality liver function test ( ≥1.5 fold normal upper limit level Lalanine aminotransferase ( ALT ) , Laspartate aminotransferase ( AST ) total bilirubin ) Unable bear pH meter catheter insertion History symptomatic GERD , erosive esophagitis , duodenal ulcer , gastric ulcer , Barrett 's esophagus , ZollingerEllison syndrome Clinically significant observation consider unsuitable base medical judgment investigator</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>